查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1861257

神经基因检测：全球市场占有率和排名、总销售额和需求预测（2025-2031 年）

Neurogenetic Testing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 93 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球神经遗传学检测市场预计在 2024 年达到 6.85 亿美元，预计到 2031 年将达到 15.01 亿美元，2025 年至 2031 年的复合年增长率为 11.7%。

神经基因检测是一种分子和基因组诊断方法，用于分析和解读与神经系统疾病相关的基因。此检测可以识别个体是否携带可能导致神经退化性疾病、癫痫、智能障碍、泛自闭症障碍、运动障碍以及某些遗传性神经病变的基因突变。神经基因检测的价值不仅在于疾病的早期筛检和临床诊断，还在于指南医生製定个人化的治疗方案，并帮助家庭进行遗传风险评估和生育规划。

主要企业包括 Quest Diagnostics、Mayo Clinic、GeneDx、Illumina、Labcorp 等。前五名製造商约占全球市场份额的 30%。

北美是最大的市场，占市场份额的 30% 以上，其次是欧洲和亚太地区，分别占市场份额的约 32% 和 20%。

按产品划分，EXOME定序是最大的细分市场，约占 45% 的份额。按应用划分，医院是最大的应用领域，占 45% 以上的份额，其次是专科诊所、研究机构和诊断实验室。

随着阿兹海默症、帕金森氏症、癫痫和泛自闭症障碍等疾病的临床负担日益加重，基因检测正成为早期诊断、风险预测和个人化治疗的重要工具。次世代定序（NGS）、全EXOME定序（WES）和全基因测序（WGS）技术的进步显着降低了成本，同时提高了准确性和效率，加速了其在临床上的应用。同时，製药公司和医疗机构正日益将神经遗传学检测整合到药物研发和临床试验中，以识别潜在的治疗标靶和伴随诊断方法。

本报告旨在对全球神经遗传检测市场进行全面分析，重点关注总收入、企业市场占有率和主要企业的排名，以及按地区/国家、类型和应用对神经遗传检测进行分析。

本报告以销售收入为指标，对神经遗传学检测市场规模、估算和预测进行了呈现，以 2024 年为基准年，并包含了 2020 年至 2031 年的历史数据和预测数据。报告运用定量和定性分析，帮助读者制定神经遗传学检测业务/成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Quest Diagnostics
  • Mayo Clinic
  • GeneDx
  • Illumina
  • Labcorp（Invitae/MNG Laboratories）
  • MedGenome Labs
  • Connecticut Children's
  • CENTOGENE
  • Victorian Clinical Genetics Services
  • PacBio

按类型分類的细分市场

  • EXOME定序
  • 全基因测序
  • RNA定序
  • 常见DNA检测

应用领域

  • 医院
  • 专科诊所
  • 研究所
  • 诊断实验室

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Neurogenetic Testing was estimated to be worth US$ 685 million in 2024 and is forecast to a readjusted size of US$ 1501 million by 2031 with a CAGR of 11.7% during the forecast period 2025-2031.

Neurogenetic testing is a molecular and genomic diagnostic approach used to analyze and interpret genes associated with neurological disorders. This testing helps identify whether an individual carries genetic mutations that may cause neurodegenerative diseases, epilepsy, intellectual disability, autism spectrum disorders, movement disorders, and certain hereditary neuropathies. The value of neurogenetic testing lies not only in early disease screening and clinical diagnosis, but also in guiding physicians to develop personalized treatment plans and assisting families with genetic risk assessment and reproductive planning.

Global neurogenetic testing players include Quest Diagnostics, Mayo Clinic, GeneDx, Illumina and Labcorp, etc. Global top five manufacturers hold a share about 30%.

The largest market is North America, has a share over 30%, followed by Europe and Asia Pacific, with around 32% and 20% market share respectively.

In terms of product, Exome Sequencing is the largest segment, with a share about 45%. And in terms of application, the largest application is Hospitals, has a share over 45%, followed by Specialty Clinics, Research Institutes and Diagnostics Laboratories.

With the growing clinical burden of diseases such as Alzheimer's, Parkinson's, epilepsy, and autism spectrum disorders, genetic testing is becoming a critical tool for early diagnosis, risk prediction, and personalized treatment. Advances in next-generation sequencing (NGS), whole-exome sequencing (WES), and whole-genome sequencing (WGS) have significantly reduced costs while improving accuracy and efficiency, accelerating adoption in clinical practice. At the same time, pharmaceutical companies and healthcare providers are increasingly integrating neurogenetic testing into drug development and clinical trials to identify potential therapeutic targets and companion diagnostics.

This report aims to provide a comprehensive presentation of the global market for Neurogenetic Testing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Neurogenetic Testing by region & country, by Type, and by Application.

The Neurogenetic Testing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurogenetic Testing.

Market Segmentation

By Company

  • Quest Diagnostics
  • Mayo Clinic
  • GeneDx
  • Illumina
  • Labcorp (Invitae/MNG Laboratories)
  • MedGenome Labs
  • Connecticut Children's
  • CENTOGENE
  • Victorian Clinical Genetics Services
  • PacBio

Segment by Type

  • Exome Sequencing
  • Whole Genome Sequencing
  • RNA Sequencing
  • General DNA Testing

Segment by Application

  • Hospitals
  • Specialty Clinics
  • Research Institutes
  • Diagnostics Laboratories

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Neurogenetic Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Neurogenetic Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Neurogenetic Testing in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Neurogenetic Testing Product Introduction
  • 1.2 Global Neurogenetic Testing Market Size Forecast (2020-2031)
  • 1.3 Neurogenetic Testing Market Trends & Drivers
    • 1.3.1 Neurogenetic Testing Industry Trends
    • 1.3.2 Neurogenetic Testing Market Drivers & Opportunity
    • 1.3.3 Neurogenetic Testing Market Challenges
    • 1.3.4 Neurogenetic Testing Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Neurogenetic Testing Players Revenue Ranking (2024)
  • 2.2 Global Neurogenetic Testing Revenue by Company (2020-2025)
  • 2.3 Key Companies Neurogenetic Testing Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Neurogenetic Testing Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Neurogenetic Testing
  • 2.6 Neurogenetic Testing Market Competitive Analysis
    • 2.6.1 Neurogenetic Testing Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Neurogenetic Testing Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurogenetic Testing as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Exome Sequencing
    • 3.1.2 Whole Genome Sequencing
    • 3.1.3 RNA Sequencing
    • 3.1.4 General DNA Testing
  • 3.2 Global Neurogenetic Testing Sales Value by Type
    • 3.2.1 Global Neurogenetic Testing Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Neurogenetic Testing Sales Value, by Type (2020-2031)
    • 3.2.3 Global Neurogenetic Testing Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospitals
    • 4.1.2 Specialty Clinics
    • 4.1.3 Research Institutes
    • 4.1.4 Diagnostics Laboratories
  • 4.2 Global Neurogenetic Testing Sales Value by Application
    • 4.2.1 Global Neurogenetic Testing Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Neurogenetic Testing Sales Value, by Application (2020-2031)
    • 4.2.3 Global Neurogenetic Testing Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Neurogenetic Testing Sales Value by Region
    • 5.1.1 Global Neurogenetic Testing Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Neurogenetic Testing Sales Value by Region (2020-2025)
    • 5.1.3 Global Neurogenetic Testing Sales Value by Region (2026-2031)
    • 5.1.4 Global Neurogenetic Testing Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Neurogenetic Testing Sales Value, 2020-2031
    • 5.2.2 North America Neurogenetic Testing Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Neurogenetic Testing Sales Value, 2020-2031
    • 5.3.2 Europe Neurogenetic Testing Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Neurogenetic Testing Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Neurogenetic Testing Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Neurogenetic Testing Sales Value, 2020-2031
    • 5.5.2 South America Neurogenetic Testing Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Neurogenetic Testing Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Neurogenetic Testing Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Neurogenetic Testing Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Neurogenetic Testing Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Neurogenetic Testing Sales Value, 2020-2031
    • 6.3.2 United States Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Neurogenetic Testing Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Neurogenetic Testing Sales Value, 2020-2031
    • 6.4.2 Europe Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Neurogenetic Testing Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Neurogenetic Testing Sales Value, 2020-2031
    • 6.5.2 China Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Neurogenetic Testing Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Neurogenetic Testing Sales Value, 2020-2031
    • 6.6.2 Japan Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Neurogenetic Testing Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Neurogenetic Testing Sales Value, 2020-2031
    • 6.7.2 South Korea Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Neurogenetic Testing Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Neurogenetic Testing Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Neurogenetic Testing Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Neurogenetic Testing Sales Value, 2020-2031
    • 6.9.2 India Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Neurogenetic Testing Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Quest Diagnostics
    • 7.1.1 Quest Diagnostics Profile
    • 7.1.2 Quest Diagnostics Main Business
    • 7.1.3 Quest Diagnostics Neurogenetic Testing Products, Services and Solutions
    • 7.1.4 Quest Diagnostics Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Quest Diagnostics Recent Developments
  • 7.2 Mayo Clinic
    • 7.2.1 Mayo Clinic Profile
    • 7.2.2 Mayo Clinic Main Business
    • 7.2.3 Mayo Clinic Neurogenetic Testing Products, Services and Solutions
    • 7.2.4 Mayo Clinic Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Mayo Clinic Recent Developments
  • 7.3 GeneDx
    • 7.3.1 GeneDx Profile
    • 7.3.2 GeneDx Main Business
    • 7.3.3 GeneDx Neurogenetic Testing Products, Services and Solutions
    • 7.3.4 GeneDx Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
    • 7.3.5 GeneDx Recent Developments
  • 7.4 Illumina
    • 7.4.1 Illumina Profile
    • 7.4.2 Illumina Main Business
    • 7.4.3 Illumina Neurogenetic Testing Products, Services and Solutions
    • 7.4.4 Illumina Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Illumina Recent Developments
  • 7.5 Labcorp (Invitae/MNG Laboratories)
    • 7.5.1 Labcorp (Invitae/MNG Laboratories) Profile
    • 7.5.2 Labcorp (Invitae/MNG Laboratories) Main Business
    • 7.5.3 Labcorp (Invitae/MNG Laboratories) Neurogenetic Testing Products, Services and Solutions
    • 7.5.4 Labcorp (Invitae/MNG Laboratories) Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Labcorp (Invitae/MNG Laboratories) Recent Developments
  • 7.6 MedGenome Labs
    • 7.6.1 MedGenome Labs Profile
    • 7.6.2 MedGenome Labs Main Business
    • 7.6.3 MedGenome Labs Neurogenetic Testing Products, Services and Solutions
    • 7.6.4 MedGenome Labs Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
    • 7.6.5 MedGenome Labs Recent Developments
  • 7.7 Connecticut Children's
    • 7.7.1 Connecticut Children's Profile
    • 7.7.2 Connecticut Children's Main Business
    • 7.7.3 Connecticut Children's Neurogenetic Testing Products, Services and Solutions
    • 7.7.4 Connecticut Children's Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Connecticut Children's Recent Developments
  • 7.8 CENTOGENE
    • 7.8.1 CENTOGENE Profile
    • 7.8.2 CENTOGENE Main Business
    • 7.8.3 CENTOGENE Neurogenetic Testing Products, Services and Solutions
    • 7.8.4 CENTOGENE Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
    • 7.8.5 CENTOGENE Recent Developments
  • 7.9 Victorian Clinical Genetics Services
    • 7.9.1 Victorian Clinical Genetics Services Profile
    • 7.9.2 Victorian Clinical Genetics Services Main Business
    • 7.9.3 Victorian Clinical Genetics Services Neurogenetic Testing Products, Services and Solutions
    • 7.9.4 Victorian Clinical Genetics Services Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Victorian Clinical Genetics Services Recent Developments
  • 7.10 PacBio
    • 7.10.1 PacBio Profile
    • 7.10.2 PacBio Main Business
    • 7.10.3 PacBio Neurogenetic Testing Products, Services and Solutions
    • 7.10.4 PacBio Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
    • 7.10.5 PacBio Recent Developments

8 Industry Chain Analysis

  • 8.1 Neurogenetic Testing Industrial Chain
  • 8.2 Neurogenetic Testing Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Neurogenetic Testing Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Neurogenetic Testing Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Neurogenetic Testing Market Trends
  • Table 2. Neurogenetic Testing Market Drivers & Opportunity
  • Table 3. Neurogenetic Testing Market Challenges
  • Table 4. Neurogenetic Testing Market Restraints
  • Table 5. Global Neurogenetic Testing Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Neurogenetic Testing Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Neurogenetic Testing Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Neurogenetic Testing Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Neurogenetic Testing
  • Table 10. Global Neurogenetic Testing Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurogenetic Testing as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Neurogenetic Testing Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Neurogenetic Testing Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Neurogenetic Testing Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Neurogenetic Testing Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Neurogenetic Testing Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Neurogenetic Testing Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Neurogenetic Testing Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Neurogenetic Testing Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Neurogenetic Testing Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Neurogenetic Testing Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Neurogenetic Testing Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Neurogenetic Testing Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Neurogenetic Testing Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Neurogenetic Testing Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Neurogenetic Testing Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Neurogenetic Testing Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Neurogenetic Testing Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Neurogenetic Testing Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Quest Diagnostics Basic Information List
  • Table 32. Quest Diagnostics Description and Business Overview
  • Table 33. Quest Diagnostics Neurogenetic Testing Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Neurogenetic Testing Business of Quest Diagnostics (2020-2025)
  • Table 35. Quest Diagnostics Recent Developments
  • Table 36. Mayo Clinic Basic Information List
  • Table 37. Mayo Clinic Description and Business Overview
  • Table 38. Mayo Clinic Neurogenetic Testing Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Neurogenetic Testing Business of Mayo Clinic (2020-2025)
  • Table 40. Mayo Clinic Recent Developments
  • Table 41. GeneDx Basic Information List
  • Table 42. GeneDx Description and Business Overview
  • Table 43. GeneDx Neurogenetic Testing Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Neurogenetic Testing Business of GeneDx (2020-2025)
  • Table 45. GeneDx Recent Developments
  • Table 46. Illumina Basic Information List
  • Table 47. Illumina Description and Business Overview
  • Table 48. Illumina Neurogenetic Testing Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Neurogenetic Testing Business of Illumina (2020-2025)
  • Table 50. Illumina Recent Developments
  • Table 51. Labcorp (Invitae/MNG Laboratories) Basic Information List
  • Table 52. Labcorp (Invitae/MNG Laboratories) Description and Business Overview
  • Table 53. Labcorp (Invitae/MNG Laboratories) Neurogenetic Testing Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Neurogenetic Testing Business of Labcorp (Invitae/MNG Laboratories) (2020-2025)
  • Table 55. Labcorp (Invitae/MNG Laboratories) Recent Developments
  • Table 56. MedGenome Labs Basic Information List
  • Table 57. MedGenome Labs Description and Business Overview
  • Table 58. MedGenome Labs Neurogenetic Testing Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Neurogenetic Testing Business of MedGenome Labs (2020-2025)
  • Table 60. MedGenome Labs Recent Developments
  • Table 61. Connecticut Children's Basic Information List
  • Table 62. Connecticut Children's Description and Business Overview
  • Table 63. Connecticut Children's Neurogenetic Testing Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Neurogenetic Testing Business of Connecticut Children's (2020-2025)
  • Table 65. Connecticut Children's Recent Developments
  • Table 66. CENTOGENE Basic Information List
  • Table 67. CENTOGENE Description and Business Overview
  • Table 68. CENTOGENE Neurogenetic Testing Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Neurogenetic Testing Business of CENTOGENE (2020-2025)
  • Table 70. CENTOGENE Recent Developments
  • Table 71. Victorian Clinical Genetics Services Basic Information List
  • Table 72. Victorian Clinical Genetics Services Description and Business Overview
  • Table 73. Victorian Clinical Genetics Services Neurogenetic Testing Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Neurogenetic Testing Business of Victorian Clinical Genetics Services (2020-2025)
  • Table 75. Victorian Clinical Genetics Services Recent Developments
  • Table 76. PacBio Basic Information List
  • Table 77. PacBio Description and Business Overview
  • Table 78. PacBio Neurogenetic Testing Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Neurogenetic Testing Business of PacBio (2020-2025)
  • Table 80. PacBio Recent Developments
  • Table 81. Key Raw Materials Lists
  • Table 82. Raw Materials Key Suppliers Lists
  • Table 83. Neurogenetic Testing Downstream Customers
  • Table 84. Neurogenetic Testing Distributors List
  • Table 85. Research Programs/Design for This Report
  • Table 86. Key Data Information from Secondary Sources
  • Table 87. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Neurogenetic Testing Product Picture
  • Figure 2. Global Neurogenetic Testing Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Neurogenetic Testing Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Neurogenetic Testing Report Years Considered
  • Figure 5. Global Neurogenetic Testing Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Neurogenetic Testing Revenue in 2024
  • Figure 7. Neurogenetic Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Exome Sequencing Picture
  • Figure 9. Whole Genome Sequencing Picture
  • Figure 10. RNA Sequencing Picture
  • Figure 11. General DNA Testing Picture
  • Figure 12. Global Neurogenetic Testing Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 13. Global Neurogenetic Testing Sales Value Market Share by Type, 2024 & 2031
  • Figure 14. Product Picture of Hospitals
  • Figure 15. Product Picture of Specialty Clinics
  • Figure 16. Product Picture of Research Institutes
  • Figure 17. Product Picture of Diagnostics Laboratories
  • Figure 18. Global Neurogenetic Testing Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 19. Global Neurogenetic Testing Sales Value Market Share by Application, 2024 & 2031
  • Figure 20. North America Neurogenetic Testing Sales Value (2020-2031) & (US$ Million)
  • Figure 21. North America Neurogenetic Testing Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Europe Neurogenetic Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Europe Neurogenetic Testing Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Asia Pacific Neurogenetic Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Asia Pacific Neurogenetic Testing Sales Value by Region (%), 2024 VS 2031
  • Figure 26. South America Neurogenetic Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. South America Neurogenetic Testing Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Middle East & Africa Neurogenetic Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. Middle East & Africa Neurogenetic Testing Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Key Countries/Regions Neurogenetic Testing Sales Value (%), (2020-2031)
  • Figure 31. United States Neurogenetic Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. United States Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 33. United States Neurogenetic Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 34. Europe Neurogenetic Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Europe Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 36. Europe Neurogenetic Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 37. China Neurogenetic Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. China Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 39. China Neurogenetic Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 40. Japan Neurogenetic Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. Japan Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 42. Japan Neurogenetic Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 43. South Korea Neurogenetic Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. South Korea Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 45. South Korea Neurogenetic Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 46. Southeast Asia Neurogenetic Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. Southeast Asia Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 48. Southeast Asia Neurogenetic Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 49. India Neurogenetic Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 50. India Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 51. India Neurogenetic Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 52. Neurogenetic Testing Industrial Chain
  • Figure 53. Neurogenetic Testing Manufacturing Cost Structure
  • Figure 54. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 55. Bottom-up and Top-down Approaches for This Report
  • Figure 56. Data Triangulation
  • Figure 57. Key Executives Interviewed